Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
about
Role of RANKL inhibition in osteoporosisAlendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenEtidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenRisedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenRisedronate for the prevention and treatment of postmenopausal osteoporosisEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceFRAX and the assessment of fracture probability in men and women from the UKOsteoporosis and its managementIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisHormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trialsEffect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonatesAre osteoporotic fractures being adequately investigated? A questionnaire of GP & orthopaedic surgeonsSurgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature reviewBisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchOsteoporosis Treatment: When to Discontinue and When to Re-startUpdates on mechanism of action and clinical efficacy of risedronate in osteoporosisTreatment of primary osteoporosis in menBisphosphonate drug holiday: choosing appropriate candidatesDenosumab for the treatment of osteoporosisAn overview on the treatment of postmenopausal osteoporosisDenosumab: mechanism of action and clinical outcomesBone anabolics in osteoporosis: Actuality and perspectivesBisphosphonates: from bench to bedsideUpdate on bazedoxifene: a novel selective estrogen receptor modulatorRecent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meetingOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.Efficacy of Osteoporosis Therapies in Diabetic Patients.A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataTeriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.Odanacatib for the treatment of postmenopausal osteoporosis.Treatment of postmenopausal osteoporosis with odanacatib.Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.Comparative statistical analysis of osteoporosis treatment based on Hungarian claims data and interpretation of the results in respect to cost-effectiveness.The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
P2860
Q21195417-EE5B9ACE-D9F6-4EAD-9061-05B52B4EEC7EQ24242258-4290C1E6-270A-40B7-8731-C1A416AF52BDQ24242665-AAB1C9AB-0846-4C91-B9F3-DCA186AB9288Q24242674-04B8DBAA-82CF-42E8-B833-E45535C9BF4EQ24245000-CBA05581-69A9-4A62-9A23-268BBEC03EE8Q24612411-8C09AA46-11EC-4122-AE0C-AE0C644310E8Q24644708-FBD87040-2C55-4BBD-9121-09063AA1DC60Q24654123-30966D85-4F80-47A1-8873-B94419D63921Q24670075-490F3551-8244-4C52-8D2D-768F6AE5C560Q24680238-F540BA2F-D8BC-4621-890E-270257B70DF0Q24795111-D98E5485-1BE0-461C-9D6E-55F30164606BQ24802074-D4EFF776-C1CC-419A-A5B6-8A1C1377394CQ25257801-22AB305E-C278-479E-A305-8409D3D6EC58Q26744057-A568EE39-D2B1-45C1-89DC-E69171538D26Q26749442-173E9FCB-2380-43DE-9014-2CF4E5FF540AQ26782621-CA459914-60DA-47E9-A095-E38E2CB42C45Q26858980-D810240F-4938-4F9C-A462-10B3B74ABA11Q26864549-B1365329-4A00-4C4A-BCFF-05892F5B91A8Q26991748-8D19D637-3759-4682-B769-129E16DF0096Q27004682-FB07591F-AD99-4D7C-A3F2-9C4602251F08Q27009275-C3C614B2-973A-4017-BECC-FD0684EFA313Q27013070-F5684279-6A8E-4F98-AB29-FC190AF61E4AQ27015899-465D06B0-DC67-4A03-953A-62D5385AC830Q27691122-FFA63201-E6BA-47CA-8962-CEFC3BE7E3D7Q28251212-711231D1-A8D9-4E2E-8BD2-FD29F080DCE9Q28258998-9859CE49-3A13-46A8-9C36-5EF2A7294496Q28552191-C1D144F5-EBB4-40D3-9428-CDD33F727B97Q30234621-BCEA42AE-3B31-4B33-BCA9-BE680BBF2416Q30235173-C5DFBE99-AAC7-4413-8B73-FBAB817BE77EQ30248756-72B6D1EC-7558-4AD5-93BB-5C44140FDF62Q30248776-0843AD5D-D623-4DE0-9BAC-28C23CC858C5Q30577427-DC0B961C-9AF1-442F-96D1-1537E81F0DA9Q30627873-4A50CFDD-6272-44E4-B56E-004A29B44293Q30683504-B3F5F4E6-C8AF-4866-A3D4-36D40A17B1DAQ30740996-184DA6A2-E051-47A1-ABB5-18D040DF4E55Q30755058-0640B19F-D23C-4720-B882-C3A4B7438F66Q30819137-72303B86-5432-40E7-9592-2E363D393327Q30967433-543CF618-012B-4EFC-87B4-809F48E854EAQ30992843-72FC5258-9099-41BE-9D9D-3654E3DD9E0CQ31145542-C6CA6474-3C95-45CE-ABEC-0F9CD3B6054F
P2860
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effect of risedronate on the r ...... ervention Program Study Group.
@ast
Effect of risedronate on the r ...... ervention Program Study Group.
@en
type
label
Effect of risedronate on the r ...... ervention Program Study Group.
@ast
Effect of risedronate on the r ...... ervention Program Study Group.
@en
prefLabel
Effect of risedronate on the r ...... ervention Program Study Group.
@ast
Effect of risedronate on the r ...... ervention Program Study Group.
@en
P2093
P1476
Effect of risedronate on the r ...... tervention Program Study Group
@en
P2093
Hip Intervention Program Study Group
I Fogelman
J Y Reginster
P D Miller
P J Meunier
P304
P356
10.1056/NEJM200102013440503
P407
P577
2001-02-01T00:00:00Z